文献速递类风湿关节炎

Syntenin-1介导的致关节炎性通过重编程类风湿关节炎代谢巨噬细胞和Th1细胞而增强

Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells.
PubMed 文献 · Ann Rheum Dis · 2023-01-02

研究探讨Syntenin-1在类风湿关节炎(RA)中的细胞来源、免疫调节和分子机制。Syntenin-1与SDC-1在RA滑膜巨噬细胞和内皮细胞共定位,血液Syntenin-1和滑膜SDC-1转录组与抗环瓜氨酸肽抗体、红细胞沉降率、滑膜厚度和骨侵蚀相关。Syntenin-1通过SDC-1和mTOR信号重编程代谢性巨噬细胞,并经IL-12和IL-18交叉调节Th1细胞,驱动炎症和代谢网络及破骨细胞分化。

要点

  • Syntenin-1与SDC-1在RA滑膜巨噬细胞和内皮细胞共定位,并与抗环瓜氨酸肽抗体、红细胞沉降率、滑膜厚度和骨侵蚀相关
  • Syntenin-1通过SDC-1、葡萄糖摄取和mTOR信号重编程代谢性巨噬细胞,IL-5R和PDZ1抑制无效
  • Syntenin-1经SDC-1连接和RANK、CTSK、NFATc1转录上调促使RA和关节髓系细胞分化为破骨细胞

核心结论

  • Syntenin-1/SDC-1通路通过糖酵解巨噬细胞和Th1细胞交叉调节在RA炎症和代谢格局中起关键作用。

研究设计与样本

  • 使用RA患者髓系和淋巴系细胞以及临床前模型研究Syntenin-1/SDC-1对炎症和代谢格局的影响。

主要发现

  • Syntenin-1和SDC-1共定位于RA滑膜巨噬细胞和内皮细胞。
  • 血液Syntenin-1和滑膜SDC-1转录组与抗环瓜氨酸肽抗体、红细胞沉降率、滑膜厚度和骨侵蚀相关。
  • 经Syntenin-1重编程的代谢性CD14+CD86+GLUT1+巨噬细胞表达多种促炎干扰素转录因子、单核因子和糖酵解因子,氧化中间产物减少,且被SDC-1阻断、葡萄糖摄取抑制和/或mTOR信号抑制所下调。
  • IL-5R和PDZ1抑制对经Syntenin-1重编程的RA巨噬细胞无效。
  • 在Syntenin-1诱导的关节炎中,F4/80+iNOS+RAPTOR+巨噬细胞代表糖酵解RA巨噬细胞,放大炎症和糖酵解网络;这些网络在SDC-1-/-动物中被消除,而关节促修复单核因子不受影响,氧化代谢物适度补充。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Syntenin-1, a novel endogenous ligand, was discovered to be enriched in rheumatoid arthritis (RA) specimens compared with osteoarthritis synovial fluid and normal synovial tissue (ST). However, the cellular origin, immunoregulation and molecular mechanism of syntenin-1 are undescribed in RA. METHODS: RA patient myeloid and lymphoid cells, as well as preclinical models, were used to investigate the impact of syntenin-1/syndecan-1 on the inflammatory and metabolic landscape. RESULTS: Syntenin-1 and syndecan-1 (SDC-1) co-localise on RA ST macrophages (MΦs) and endothelial cells. Intriguingly, blood syntenin-1 and ST SDC-1 transcriptome are linked to cyclic citrullinated peptide, erythrocyte sedimentation rate, ST thickness and bone erosion. Metabolic CD14+CD86+GLUT1+MΦs reprogrammed by syntenin-1 exhibit a wide range of proinflammatory interferon transcription factors, monokines and glycolytic factors, along with reduced oxidative intermediates that are downregulated by blockade of SDC-1, glucose uptake and/or mTOR signalling. Inversely, IL-5R and PDZ1 inhibition are ineffective on RA MΦs-reprogrammed by syntenin-1. In syntenin-1-induced arthritis, F4/80+iNOS+RAPTOR+MΦs represent glycolytic RA MΦs, by amplifying the inflammatory and glycolytic networks. Those networks are abrogated in SDC-1-/- animals, while joint prorepair monokines are unaffected and the oxidative metabolites are moderately replenished. In RA cells and/or preclinical model, syntenin-1-induced arthritogenicity is dependent on mTOR-activated MΦ remodelling and its ability to cross-regulate Th1 cells via IL-12 and IL-18 induction. Moreover, RA and joint myeloid cells exposed to Syntenin-1 are primed to transform into osteoclasts via SDC-1 ligation and RANK, CTSK and NFATc1 transcriptional upregulation. CONCLUSION: The syntenin-1/SDC-1 pathway plays a critical role in the inflammatory and metabolic landscape of RA through glycolytic MΦ and Th1 cell cross-regulation (graphical abstract).

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Meyer A, Sienes RE, Nijim W, et al. Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells. Ann Rheum Dis. 2023. PMID: 36593091. doi:10.1136/ard-2022-223284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。